Swedish clinical-stage pharmaceutical company Vicore Pharma Holding AB (STO:VICO) announced on Friday an exclusive licensing agreement with Japanese pharmaceutical company Nippon Shinyaku Co Ltd, granting rights for the development and commercialisation of Vicore's drug candidate C21 in Japan.
Vicore will receive an upfront payment of USD10m and stands to gain up to USD275m in milestone payments, along with tiered royalty payments.
Nippon Shinyaku will initially focus on developing C21 for idiopathic pulmonary fibrosis (IPF), aiming to address the limited treatment options for approximately 34,000 patients in Japan.
Vicore retains all rights to C21 outside of Japan.
C21, an oral therapy, has shown promising results in stabilising or improving lung function in IPF patients. A global Phase 2b ASPIRE study is planned to begin in the first half of this year.
Indivior updates on Aelis Farma's Phase 2B study of AEF0117 for Cannabis Use Disorder
Vesper Bio announces positive Phase I results for FTD treatment
Empower Pharmacy names new president
Innovent's IBI363 receives US FDA Fast Track Designation
Valneva and Pfizer report positive Phase 2 booster results for Lyme disease vaccine
Grit Biotechnology's GT201 receives US FDA IND approval
Cereno Scientific doses first patient in Expanded Access Program for PAH
Medicilon USA begins operations at second R&D centre in Massachusetts
CS Genetics names new chief operating officer and chief scientific officer
Expanse Medical names new chief executive officer and FlowPhysix board member